Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m once per week with intravenous (IV) carbo...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 37; číslo 16; s. 1380
Hlavní autori:	Walker, Joan L, Brady, Mark F, Wenzel, Lari, Fleming, Gini F, Huang, Helen Q, DiSilvestro, Paul A, Fujiwara, Keiichi, Alberts, David S, Zheng, Wenxin, Tewari, Krishnansu S, Cohn, David E, Powell, Matthew A, Van Le, Linda, Davidson, Susan A, Gray, Heidi J, Rose, Peter G, Aghajanian, Carol, Myers, Tashanna, Alvarez Secord, Angeles, Rubin, Stephen C, Mannel, Robert S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.06.2019
Predmet:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Bevacizumab - administration & dosage Bevacizumab - adverse effects Carboplatin - administration & dosage Carboplatin - adverse effects Disease Progression Drug Administration Schedule Female Humans Infusions, Intravenous Infusions, Parenteral Middle Aged Neoplasm Staging Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Paclitaxel - adverse effects Progression-Free Survival Time Factors United States United States
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!